Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy dementia to Alzheimer’s disease. Read More
Location: United States
Employees: 11-50
Total raised: $15.36M
Founded date: 2006
Funding Rounds 7
| Date | Series | Amount | Investors |
| 18.06.2026 | - | $1.9M | National I... |
| 05.06.2022 | Series B | $2.7M | - |
| 15.09.2020 | Grant | $3.19M | - |
| 10.10.2019 | Grant | $2.18M | - |
| 02.10.2018 | Grant | $2.49M | - |
| 22.05.2013 | Series B | $2.8M | - |
| 23.04.2012 | Series A | $2M | - |
Mentions in press and media 6
| Date | Title | Description |
| 18.06.2026 | Oligomerix Awarded $1.9 Million NIH Grant For Alzheimer’s Disease Safety Studies | Oligomerix announced that it has received a $1.9 million NIH Fast-Track Phase II award from the National Institute on Aging of the National Institutes of Health. The grant will support clinical development of OLX-07010, an orally administer... |
| 05.06.2022 | Oligomerix Closes $2.7M Series B Extension | Oligomerix, a White Plains, New York-based clinical stage biotechnology company, raised $2.7M in Series B funding. The backers were not disclosed. The company intends to use the funds to to accelerate its transition into Phase 1 human clini... |
| 15.04.2015 | Startup raising $3M for drug approach that inhibits tau aggregation in Alzheimer’s disease | Small molecule inhibitors of tau oligomer formation (NIH, ADDF) Tau oligomer specific antibody discovery and development (NIH) In vivo tau oligomer mouse model for drug screening (ADDF) Tau oligomer specific protease target Tau Oligomer Bio... |
| 22.05.2013 | Oligomerix Completes $2.8M Series B Financing | Oligomerix, Inc., a New York, NY-based biopharmaceutical company, completed a $2.8m Series B financing. Investors were not disclosed. Founded in 2006 and led by James Moe, Ph.D., MBA, president and CEO, Oligomerix develops disease modifying... |
| 23.04.2012 | Oligomerix Completes $2M in Series A Financing | Oligomerix, Inc., a company that develops disease modifying therapeutics for Alzheimer’s disease and related neurodegenerative disorders, has completed approximately $2m in Series A financing. Backers in the financing, which includes both i... |
| - | Startup raising $3M for drug approach that inhibits tau aggregation in Alzheimer’s disease | Protein misfolding – and resultant tau aggregation – has long been fingered as causative of Alzheimer’s and other neurodegenerative disease. New York startup Oligomerix is addressing this issue with a host of drug development programs under... |